Study on the mechanism of photodynamic therapy mediated by 5-aminoketovalerate in human ovarian cancer cell line.
5-ALA
Apoptosis
Caspase-3
Cell death
Photodynamic therapy
Journal
Lasers in medical science
ISSN: 1435-604X
Titre abrégé: Lasers Med Sci
Pays: England
ID NLM: 8611515
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
01
08
2020
accepted:
16
12
2020
pubmed:
5
1
2021
medline:
18
11
2021
entrez:
4
1
2021
Statut:
ppublish
Résumé
We aimed to investigate the mechanism and effect of photodynamic treatment mediated by 5-aminoketovalerate (5-ALA-PDT) on human ovarian cancer cells (OVCAR3 cells) and to provide a theoretical basis for the subsequent experimental step in vivo. Human ovarian cancer OVCAR3 cells were randomly divided into four groups: control group, laser irradiation alone group, photosensitizer alone group, and photodynamic treatment group. Alterations in cell morphology were observed with an inverted light microscope; cell viability was examined by CCK-8 assays. The ROS content and apoptosis rate were examined by flow cytometry analysis. Western blot was used to detect the expression of apoptosis-related proteins, such as caspase-3, Bax, and Bcl-2, and the expression of cleaved caspase-3 in live cells was detected by a cleaved caspase-3 assay kit. Inverted light microscopy showed alterations in cell morphology in different stages. Comparison with the three other groups indicated that tumor cell proliferation was significantly decreased in the photodynamic treatment group (P < 0.05). Flow cytometry analysis revealed that the content of ROS was higher in the photodynamic group than in the other three groups, and the apoptosis rate was higher in the photodynamic treatment group. The difference compared with the other three groups was statistically significant (P < 0.001). The western blot results indicated that the protein expression of Bcl-2 and caspase-3 was decreased in the photodynamic treatment group, and the protein expression level of Bax was increased (P < 0.05). The expression of cleaved caspase-3 was increased in the photodynamic treatment group compared with the other groups according to the data obtained with a microplate reader. Thus, our results demonstrated that the apoptosis and viability of OVCAR3 cells are altered in response to 5-ALA-PDT; however, no remarkable effects were observed in ovarian cancer cells treated with laser irradiation or photosensitizer alone. 5-ALA-PDT can significantly inhibit the growth of human ovarian cancer cells, and the mechanism of this effect is related to the tumor cell apoptosis mediated by the downregulation of Bcl-2 and caspase-3 and upregulation of Bax protein expression.
Identifiants
pubmed: 33392781
doi: 10.1007/s10103-020-03226-5
pii: 10.1007/s10103-020-03226-5
doi:
Substances chimiques
Photosensitizing Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1873-1881Subventions
Organisme : National Natural Science Foundation of China
ID : 61775128
Organisme : National Natural Science Foundation of China
ID : 61975105
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag London Ltd. part of Springer Nature.
Références
Hopper C (2000) Photodynamic therapy: a clinical reality in the treatment of cancer. Lancet Oncol 1(4):212–219
doi: 10.1016/S1470-2045(00)00166-2
Sanfilippo NJ et al (2001) Toxicity of photodynamic therapy after combined external beam radiotherapy and intraluminal brachytherapy for carcinoma of the upper aerodigestive tract. Lasers Surg Med 28(3):278–281
doi: 10.1002/lsm.1051
Xu P et al (2012) Receptor-targeting phthalocyanine photosensitizer for improving antitumor photocytotoxicity. PLoS One 7(5):e37051
doi: 10.1371/journal.pone.0037051
Woźniak M et al (2018) The effect of in vitro photodynamic therapy on increase of osteopontin and heat shock protein 70 expression in squamous cell and colon carcinoma. IEEE J Select Topics Quant Electron 25(1):1–7
doi: 10.1109/JSTQE.2018.2846038
Maloth KN et al (2016) Photodynamic therapy - a non-invasive treatment modality for precancerous lesions. J Lasers Med Sci 7(1):30
doi: 10.15171/jlms.2016.07
Agostini P et al (2011) Photodynamic therapy of cancer: an update. CA Cancer J Clin 61(4):250–281
doi: 10.3322/caac.20114
Paul M, Shashikant L (2016) Photodynamic therapy in gynecologic malignancies: a review of the Roswell park cancer institute experience. Cancers (Basel) 8(10):88
doi: 10.3390/cancers8100088
Macdonald IJ, Dougherty TJ (2001) Basic principles of photodynamic therapy. J Porphyrins Phthalocyanines 5(2):105–129
doi: 10.1002/jpp.328
Debele TA, Peng S, Tsai HC (2015) Drug carrier for photodynamic Cancer therapy. Int J Mol Sci 6(9):22094–22136
doi: 10.3390/ijms160922094
Ceylan Y, Lekili M, Muezzinoglu T, Nese N, Isisag A (2016) Predictive value of cyclooxygenase-2 over expression for identifying prostate cancer from benign prostatic hyperplasia in prostate biopsy specimens. Minerva Urol Nefrol 68(3):255–262
pubmed: 26125280
Abrahamse H et al (2016) New photosensitizers for photodynamic therapy. Biochem J 473(4):347–364
doi: 10.1042/BJ20150942
Rkein AM, Ozog DM (2014) Photodynamic therapy. Dermatol Clin 32:415–425
doi: 10.1016/j.det.2014.03.009
Abrahamse H, Kruger CA, Kadanyo S et al (2017) Nanoparticles for advanced photodynamic therapy of cancer. Photomed Laser Surg 35(11):581–588
doi: 10.1089/pho.2017.4308
Battah S, Hider RC, MacRobert AJ et al (2017) Hydroxypyridinone and 5-Aminolaevulinic acid conjugates for photodynamic therapy. J Med Chem 60(8):3498–3510
doi: 10.1021/acs.jmedchem.7b00346
Evans S, Matthews W, Perry R, Fraker D, Norton J, Pass HI (1990) Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. J Natl Cancer Inst 82(1):34–39
doi: 10.1093/jnci/82.1.34
Henderson BW, Dougherty TJ (1992) How does photodynamic therapy work? Photochem Photobiol 55(1):145–157
doi: 10.1111/j.1751-1097.1992.tb04222.x
Wagner M et al (2012) Methylene blue photodynamic therapy in malignant melanoma decreases expression of proliferating cell nuclear antigen and heparanases. Clin Exp Dermatol 37(5):527–533
doi: 10.1111/j.1365-2230.2011.04291.x
Erdoğmuş A, Nyokong T (2010) Synthesis of zinc phthalocyanine derivatives with improved photophysicochemical properties in aqueous media. J Mol Struct 977(1):26–38
doi: 10.1016/j.molstruc.2010.04.048
Josefsen LB, Boyle RW (2012) Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics. Theranostics 2(9):916–966
doi: 10.7150/thno.4571
Chang JE, Yoon IS, Sun PL et al (2014) Anticancer efficacy of photodynamic therapy with hematoporphyrin-modified, doxorubicin-loaded nanoparticles in liver cancer. J Photochem Photobiol B 140:49–56
doi: 10.1016/j.jphotobiol.2014.07.005
Akbarzadeh F, Khoshgard K, Arkan E et al (2018) Evaluating the photodynamic therapy efficacy using 5-aminolevulinic acid and folic acid-conjugated bismuth oxide nanoparticles on human nasopharyngeal carcinoma cell line. Artif Cells Nanomed Biotechnol 46(sup3):S514–S523
doi: 10.1080/21691401.2018.1501376
Zamani ARN, Mashayekhi MR, Jadid MFS, Faridvand Y, Tajalli H, Rahbarghazi R (2018) Photo-modulation of zinc phthalocyanine-treated breast cancer cell line ZR-75-1 inhibited the normal tumor activity in vitro. Lasers Med Sci 33(9):1969–1978
doi: 10.1007/s10103-018-2563-0
Chilakamarthi U, Giribabu L (2017) Photodynamic therapy: past, present and future. Chem Rec 17(8):775–802
doi: 10.1002/tcr.201600121
Lucena SR, Salazar N, Gracia-Cazaña T et al (2015) Combined treatments with photodynamic therapy for non-melanoma skin cancer. Int J Mol Sci 16(10):25912–25933
doi: 10.3390/ijms161025912
Malik Z, Lugaci H (1987) Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins. Br J Cancer 56(5):589–595
doi: 10.1038/bjc.1987.246
Nakai Y, Tatsumi Y, Miyake M et al (2016) Expression of ferrochelatase has a strong correlation in protoporphyrin IX accumulation with photodynamic detection of bladder cancer. Photodiagn Photodyn Ther 13(2):225–232
doi: 10.1016/j.pdpdt.2015.07.174
Hayata Y, Kato H, Konaka C, Ono J, Matsushima Y, Yoneyama K et al (2001) Hematoporphyrin derivative and laser photoradiation in the treatment of lung cancer. Chest 81(3):269–277
doi: 10.1378/chest.81.3.269
Cortese DA, Edell ES, Kinsey JH (1997) Photodynamic therapy for early stage squamous cell carcinoma of the lung. Mayo Clin Proc 72(7):595–602
doi: 10.1016/S0025-6196(11)63563-5
Usuda J et al (2006) Photodynamic therapy (PDT) for lung cancers. J Thorac Oncol 1(5):489–493
doi: 10.1016/S1556-0864(15)31616-6
Usuda J et al (2011) Molecular determinants of photodynamic therapy for lung cancers. Lasers Surg Med 43(7):591–599
doi: 10.1002/lsm.21097
Furuse K et al (1993) A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. J Clin Oncol 11(10):1852–1857
doi: 10.1200/JCO.1993.11.10.1852
Kato H et al (2006) Basic and clinical research on photodynamic therapy at Tokyo Medical University hospital. Lasers Surg Med 38(5):371–375
doi: 10.1002/lsm.20346
Kato H et al (2003) Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorine e6 and diode laser for early superficial squamous cell carcinoma of the lung. Lung Cancer 42(1):103–111
doi: 10.1016/S0169-5002(03)00242-3
Engbrecht BW et al (1999) Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model. Cancer Res 59(17):4334
pubmed: 10485481
Wang Y et al (2016) A photodynamic therapy combined with topical 5-aminolevulinic acid and systemic hematoporphyrin derivative is more efficient but less phototoxic for cancer. J Cancer Res Clin Oncol 142(4):813–821
doi: 10.1007/s00432-015-2066-3
Dolmans DE, Fukumura D, Jain RK (2003) Photodynamic therapy for cancer. Nat Rev Cancer 3(5):380–387
doi: 10.1038/nrc1071